KANAZAWA Takanori

J-GLOBAL         Last updated: Jul 2, 2019 at 03:16
 
Avatar
Name
KANAZAWA Takanori
Affiliation
Nihon University
Section
School of Pharmacy, Department of Pharmacy
Job title
Assistant Professor

Research Areas

 
 

Academic & Professional Experience

 
Apr 2006
 - 
Dec 2010
助手, 薬学部, 東京薬科大学
 
Jan 2011
 - 
Mar 2016
助教, 薬学研究科, 東京薬科大学大学院
 
Jan 2011
 - 
Mar 2016
助教, 薬学部, 東京薬科大学
 
Apr 2014
 - 
Mar 2015
Visiting Assistant Professor, Center for Pharmaceutical Biotechnology and nanomedicine, Northeastern University
 
Apr 2016
 - 
Mar 2017
講師, 薬学部, 東京薬科大学
 

Awards & Honors

 
May 2019
機能性ペプチドを基盤とする非侵襲的な核酸医薬DDSの開発, 2019年度奨励賞(個人), 公益社団法人 日本薬剤学会
 
Jul 2017
Elsevier Outstanding Reviewer Award 2017 for International Journal of Pharmaceutics, Elsevier
 
Sep 2016
非侵襲的な脳内への薬物送達技術の開発と脳神経疾患治療への応用, 平成28年度 日本薬学会 関東支部 奨励賞(個人), 日本薬学会 関東支部
 
Feb 2016
Nose-to-brain delivery of drug/siRNA with nanocarriers, APSTJ Global Education Presentation Award 2015(個人), 日本薬剤学会
 
May 2015
RelA標的ボナック核酸/STR-CH2R4H2C複合体局所投与によるアトピー性皮膚炎治療, 第15回遺伝子・デリバリ―研究会シンポジウム 奨励賞(個人), 遺伝子・デリバリ―研究会
 

Published Papers

 
Anti-RelA siRNA-encapsulated flexible liposome with tight junction-opening peptide as a non-invasive topical therapeutic for atopic dermatitis
Ibaraki T, Kanazawa T, Kurano T, Oogi C, Takashima Y, Seta Y
Bio. Pharm. Bull.   42(7) 1-11   Jul 2019   [Refereed]
Ibaraki H, Kanazawa T, Oogi C, Takashima Y, Seta Y
Journal of Drug Delivery Science and Technology   50 155-162   Jan 2019   [Refereed]
Optimum volume of water necessary for paste state of pediatric powder: Consideration based on yield value and application to generic medicine
Haruka Fukuda, Toyofumi Suzuki, Kaname Hashizaki, Sayaka Yoshimura, Chika Kobayashi, Yosiko Omotani, Naoto Suzuki, Takanori Kanazawa, Toshiro Fukami, Yoshihisa Yamamoto
Yakugaku-Zasshi   139 299-308   2018   [Refereed]
Kanazawa T., Fukuda M., Suzuki N., Suzuki T.
J. Vis. Exp.   141 e58485   2018   [Refereed][Invited]
Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide
Ibaraki H., Kanazawa T., Takashima Y., Okada H., Seta Y.
International Journal of Pharmaceutics   542 213-220   2018   [Refereed]
Development of non-invasive drug delivery system to the brain for brain diseases therapy
Yakugaku-Zasshi   138 443-450   2018   [Refereed][Invited]
Nose-to-Brainを基盤とする脳への核酸医薬DDS
金沢貴憲
BIO Clinica   33 54-57   Jan 2018   [Invited]
Intra-articular retention and anti-arthritic effects in collagen-induced arthritis model mice by injectable small interfering RNA containing hydrogel
Kanazawa T*, Tamano K, Sogabe K, Endo T, Ibaraki H, Takashima Y, Seta Y
Biol. Pharm. Bull.   40    2017   [Refereed]
Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide
Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, Shiraishi S, Takashima Y, Suzuki T, Seta Y
International journal of pharmaceutics      2017   [Refereed]
細胞透過性ペプチド修飾高分子ミセルとNose-to-Brain経路を利用した脳へのsiRNAデリバリー
Progress in drug delivery system   26 90-96   Dec 2017
Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide
Hisako Ibaraki, Takanori Kanazawa, Yuuki Takashima, Hiroaki Okada, Yasuo Seta
Molecules   21 1979-1983   2016   [Refereed]
Systemic delivery of small interfering RNA targeting nuclear factor κB in mice with collagen-induced arthritis using arginine-histidine based oligopeptide-modified polymer nanomicelles
Takanori Kanazawa, Takahiro Endo, Naoki Arima, Hisako Ibaraki, Yuuki Takashima, Yasuo Seta
International journal of pharmaceutics   515 315-323   2016   [Refereed]
Cytoplasm-responsive delivery systems for siRNA using cell-penetrating peptide nanomicelles
Hiroaki Okada, Ko Tanaka, Takaya Ogawa, Takanori Kanazawa, Yuuki Takashima
J. Drug Del. Sci. Tech   24 3-11   2014   [Refereed][Invited]
Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.
Kanazawa T, Morisaki K, Suzuki S, Takashima Y
Molecular pharmaceutics   11(5) 1471-1478   May 2014   [Refereed]
Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles
Takanori Kanazawa*, Fuminari Akiyama, Shino Kakizaki, Yuuki Takashima, Yasuo Seta
Biomaterials   34 9220-9226   2013   [Refereed]
Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
Tanaka K, Kanazawa T, Horiuchi S, Ando T, Sugawara K, Takashima Y, Seta Y, Okada H
International journal of pharmaceutics   455 40-47   Oct 2013   [Refereed]
Needle-free intravaginal DNA vaccination using a stearoyl oligopeptide carrier promotes local gene expression and immune responses.
Kanazawa T, Tamura T, Yamazaki M, Takashima Y, Okada H
International journal of pharmaceutics   447 70-74   Apr 2013   [Refereed]
[Non-invasive ophthalmic liposomes for nucleic acid delivery to posterior segment of eye].
Takashima Y, Tsuchiya T, Igarashi Y, Kanazawa T, Okada H, Urtti A
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan   132 1365-1370   2012   [Refereed][Invited]
Improved intestinal absorption of a poorly water-soluble oral drug using mannitol microparticles containing a nanosolid drug dispersion.
Nishino Y, Kubota A, Kanazawa T, Takashima Y, Ozeki T, Okada H
Journal of pharmaceutical sciences   101(11) 4191-4200   Nov 2012   [Refereed]
Intranasal delivery of camptothecin-loaded tat-modified nanomicells for treatment of intracranial brain tumors.
Taki H, Kanazawa T, Akiyama F, Takashima Y, Okada H
Pharmaceuticals (Basel, Switzerland)   5(10) 1092-1102   Oct 2012   [Refereed]
Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles.
Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H
European journal of pharmaceutics and biopharmaceutics   81(3) 470-477   Aug 2012   [Refereed]
Vaginal DNA vaccination against infectious diseases transmitted through the vagina.
Kanazawa T, Takashima Y, Okada H
Frontiers in bioscience (Elite edition)   4 2340-2353   Jun 2012   [Refereed]
Development of novel gene vector and dosing device for intravaginal DNA vaccine
Takanori Kanazawa, Yuuki Takashima, Hiroaki Okada
Progress in Drug Delivery System   20 29-33   2011   [Invited]
A novel, bio-reducible gene vector containing arginine and histidine enhances gene expression.
Tanaka K, Kanazawa T, Ogawa T, Suda Y, Takashima Y, Fukuda T, Okada H.
Chemical and Pharmaceutical Bulletin   59(2) 202-207   2011
Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T, Kanazawa T, Takashima Y, Okada H
Chemical & pharmaceutical bulletin   59(2) 196-201   2011   [Refereed]
A cytoplasm-sensitive peptide vector cross-linked with dynein light chain association sequence (DLCAS) enhances gene expression.
Tanaka K, Kanazawa T, Sugawara K, Horiuchi S, Takashima Y, Okada H
International journal of pharmaceutics   419 231-234   Oct 2011   [Refereed]
Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration.
Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H
Pharmaceutical research   28(9) 2130-2139   Sep 2011   [Refereed]
Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002.
Uchida T, Kanazawa T, Kawai M, Takashima Y, Okada H
The Journal of pharmacology and experimental therapeutics   338(2) 443-450   Aug 2011   [Refereed]
The characterization of protein release from sericin film in the presence of an enzyme: towards fibroblast growth factor-2 delivery.
Nishida A, Naganuma T, Kanazawa T, Takashima Y, Yamada M, Okada H
International journal of pharmaceutics   414 193-202   Jul 2011   [Refereed]
Sustained-release of protein from biodegradable sericin film, gel and sponge.
Nishida A, Yamada M, Kanazawa T, Takashima Y, Ouchi K, Okada H
International journal of pharmaceutics   407 44-52   Apr 2011   [Refereed]
Disulfide crosslinked stearoyl carrier peptides containing arginine and histidine enhance siRNA uptake and gene silencing.
Tanaka K, Kanazawa T, Ogawa T, Takashima Y, Fukuda T, Okada H.
International Journal of Pharmaceutics   398 219-224   2010
Use of silk protein, sericin, as a sustained-release material in the form of a gel, sponge and film.
Nishida A, Yamada M, Kanazawa T, Takashima Y, Ouchi K, Okada H
Chemical & pharmaceutical bulletin   58(11) 1480-1486   Nov 2010   [Refereed]
Development of cell-penetrating peptide-modified MPEG-PCL diblock copolymeric nanoparticles for systemic gene delivery.
Tanaka K, Kanazawa T, Shibata Y, Suda Y, Fukuda T, Takashima Y, Okada H
International journal of pharmaceutics   396 229-238   Aug 2010   [Refereed]
Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector.
Kanazawa T, Takashima Y, Tamura T, Tsuchiya M, Shibata Y, Udagawa H, Okada H
International journal of pharmaceutics   396 11-16   Aug 2010   [Refereed]
Enhancement of gene transfection into human dendritic cells using cationic PLGA nanospheres with a synthesized nuclear localization signal.
Kanazawa T, Takashima Y, Murakoshi M, Nakai Y, Okada H.
International Journal of Pharmaceutics   379(1) 187-195   2009
Effective vaginal DNA delivery with high transfection efficiency is a good system for induction of higher local vaginal immune responses.
Kanazawa T, Takashima Y, Shibata Y, Tsuchiya M, Tamura T, Okada H.
Journal of Pharmacy and Pharmacology   61(11) 1457-1463   2009
Synthesis and transport activities of HIV-Tat peptide-modified cholesterol pullulan
Aki Kimura, Yosuke Kamo, Yuuki Takashima, Takanori Kanazawa, Hiroaki Okada, and Tsunehiko Fukuda.
Chemistry Letters   38(10) 970-971   2009
Multifunctional peptide gene vector: Design and evaluation of disulfide cross-linked oligo arginine
Takaya Ogawa, Takanori Kanazawa, Yumiko Suda, Yuuki Takashima, Tsunehiko Fukuda, Hiroaki Okada
Peptide Science   77-80   2008
Effects of menstrual cycle on gene transfection through mouse vagina for DNA vaccine.
Kanazawa T, Takashima Y, Hirayama S, Okada H.
International Journal of Pharmaceutics   360 164-170   2008
Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres.
Takashima Y, Saito R, Nakajima A, Oda M, Kimura A, Kanazawa T, Okada H.
International Journal of Pharmaceutics   343 262-269   2007

Misc

 
血液脳関門を迂回する鼻から脳への薬物送達に適した鼻腔内製剤の開発を目指して
鈴木 豊史,金沢 貴憲,鈴木 直人
製剤機械技術会誌   27(2) 216-221   2018   [Invited]
siRNA delivery system for skin disorders treatment
Takashima Y., Ibaraki H., Kanazawa T.
Drug Delivery System   33(4) 206-213   Oct 2018   [Invited]
機能性ナノミセルとNose-to-Brainデリバリーを基盤とする脳中枢への核酸医薬DDS
金沢貴憲
アグリバイオ   2 1079-1082   Sep 2018   [Invited]
Drug delivery system across or bypassing the blood-brain barrier to be a key point for development of the therapeutic medicine for central nerve system disorders.
Kanazawa T., Suzuki N., Suzuki T.
Journal of Japanese Societyfor Biomaterials   36(3) 214-219   Jul 2018   [Invited]
“Druggable” biomaterials are expected as new medicines to treat central nerve system (central nervous system; CNS) disorders. However, the most of them cannot be delivered to CNS due to the dynamic barrier, which is called blood-brain barrier (BBB...
Development of siRNA DDS based on cell-penetrating peptide modified polymer micelles via intravenous, or nose-to-brain route for cancer, and brain/CNS diseases therapy
Kanazawa T
Drug Delivery System   32(4) 224-225   2017   [Invited]

Books etc

 
Mucosal delivery of biopharmaceuticals: Biology, challenges and strategies
Takanori Kanazawa, Hiroaki Okada (Part:Joint Work, Delivery strategies for developing vaginal DNA vaccine combinating cell-penetrating peptide and jet injection)
Springer Science+Business Media New York   2014   
ドラッグデリバリーシステムの新展開II ―核酸医薬・抗体医薬・ワクチン医療を支えるDDS技術―
岡田弘晃, 小河崇也, 田中晃, 金沢貴憲 (Part:Joint Work, 細胞質感受性核酸DDS)
2012   
次世代バイオ医薬品の製剤設計と開発戦略
岡田弘晃, 金沢貴憲 (Part:Joint Work, 膣粘膜DNAワクチン)
シーエムシー出版   2011   

Conference Activities & Talks

 
中枢領域を標的とする医薬品開発における Nose-to-Brain研究の現状とその将来展望 [Invited]
金沢貴憲
第56回薬剤学懇談会研究討論会   14 Jun 2019   
中枢疾患を標的とする非侵襲的核酸医薬DDS技術 [Invited]
金沢貴憲
ラウンドテーブル5 「次世代を担う核酸医薬DDS技術の新領域」,日本薬剤学会 第34年会   18 May 2019   
機能性ペプチドを基盤とする 非侵襲的な核酸医薬DDSの開発 [Invited]
金沢貴憲
2019年度 奨励賞受賞講演 ,日本薬剤学会 第34年会   18 May 2019   
経鼻投与による薬物・バイオ医薬の 脳内デリバリー動態と中枢疾患治療への応用 [Invited]
金沢貴憲,鈴木直人,鈴木豊史
学術シンポジウム 2 「経肺経鼻投与型製剤の設計と体内動態の評価」,日本薬剤学会 第34年会   16 May 2019   
中・高分子医薬のNose-to-Brainデリバリーによる中枢疾患治療 [Invited]
金沢貴憲,鈴木直人,鈴木豊史
シンポジウム「脳内薬物デリバリー研究の潮流 ~薬物治療の実現を目指して~」, 日本薬学会139年会   21 Mar 2019   日本薬学会

Research Grants & Projects

 
ナノマテリアルを活用した水溶性薬物のNose-to-Brainデリバリーの高効率化と脊髄疾患治療への応用
Project Year: Apr 2019 - Mar 2020
脳虚血部位標的指向型Nose-to-Brain DDS技術の開発
Project Year: Apr 2018 - Mar 2019    Investigator(s): 金沢貴憲
脳神経系希少疾患治療を目指した経鼻投与による脳内バイオ医薬デリバリー戦略の構築
文部科学省: 学術研究助成基金助成金(基盤研究(C))
Project Year: Apr 2017 - Mar 2020    Investigator(s): 金沢 貴憲
薬物動態学的解析に基づいたバイオ医薬のNose-to-Brain移行機構の解明
Project Year: Apr 2017 - Mar 2018    Investigator(s): 金沢貴憲
脳・中枢神経系への非侵襲的な薬物デリバリー法の開発を指向した経鼻投与後の脳内薬物・バイオ医薬動態解析
Project Year: Apr 2017 - Mar 2018    Investigator(s): 金沢貴憲

Patents

 
特願2019-115688 : 薬物送達用組成物および医薬組成物
金沢貴憲、小菅康弘
特願2017-135547、PCT/JP2018/26199 : 核酸送達用組成物及び核酸含有組成物
特願2013‐042237 : NF-κB RelA遺伝子の発現抑制剤、アレルギー性皮膚炎用医薬、およびその用途
金沢貴憲、瀬田康生、岡田弘晃、大木忠明、濱崎智洋、水谷隆之

Social Contribution

 
日本経済新聞朝刊 科学技術面,「バイオ医薬品届け脳治療」
[Interviewee, Media coverage cooperation]  日本経済新聞朝刊  15 Oct 2018
日経産業新聞 先端技術面,Next Tech 2030「脳へ薬 鼻神経から投入」
[]  日経産業新聞  21 Jun 2019
日経産業新聞 科学技術面 ,「次世代の先導者」 日本大学専任講師 金沢貴憲氏-核酸医薬、患部へ運搬
[Interviewee, Media coverage cooperation]  日本経済新聞  日経産業新聞  16 Sep 2019